| Literature DB >> 35520491 |
Hai Jiang1, Liu Yang1, Xudong Xing1, Meiling Yan1, Xinyue Guo1, Ajiao Hou1, Wenjing Man1, Bingyou Yang1, Qiuhong Wang1,2, Haixue Kuang1.
Abstract
The ripe fruit of Xanthium strumarium L. (Xanthii Fructus) cannot be widely used as a Chinese herbal medicine (CHM) owing to its hepatotoxicity. However, Xanthii Fructus (XF) can be used effectively and safely after correct processing based on traditional experience, although a high hepatotoxicity risk remains owing to improper usage. Therefore, the processing methods used must be clarified to ensure safety. The adenosine-5'-triphosphate (ATP) level in tissues is an important indicator reflecting the functional status of liver cells. Therefore, this study aims to evaluate the hepatotoxicity of XF using UPLC-MS/MS. The hepatotoxicity of raw XF (RXF) and XF processed by intermediary energy metabolites (PXF) is compared. The method is evaluated for its analytical performance and successfully applied to the quantification of ATP, adenosine-5'-diphosphate (ADP), adenosine-5'-monophosphate (AMP), atractyloside, and carboxyatractyloside in mouse liver. The hepatotoxicity results also indicate that the toxicity of XF is decreased after processing, perhaps due to the decrease in atractyloside and carboxyatractyloside contents. Importantly, the experimental evidence provides a rationale for the reduction in toxicity. These data show that mouse livers are damaged between the days 20 and 30 of RXF oral administration, and that the ATP level is decreased. Importantly, no significant difference is observed between the PXF treatment group and control group, while the RXF treatment group is significantly different. Therefore, processing can reduce the toxicity of XF. This journal is © The Royal Society of Chemistry.Entities:
Year: 2019 PMID: 35520491 PMCID: PMC9059864 DOI: 10.1039/c8ra08272c
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Optimized SRM parameters of five analytes and IS
| Peak no. | Analytes | Retention time (min) | Precursor ion ([M − H]−) ( | Product ion ( | Collision energy (V) | Dwell time (s) |
|---|---|---|---|---|---|---|
| 1 | ATP | 0.97 | 506 | 273 | 26.83 | 0.8 |
| 408 | 19.67 | |||||
| 2 | ADP | 0.98 | 426 | 328 | 16.56 | 0.8 |
| 408 | 18.98 | |||||
| 3 | AMP | 0.99 | 346 | 134 | 31.34 | 0.8 |
| 150 | 20.65 | |||||
| 4 | CATR | 3.85 | 769.3 | 543 | 17.58 | 0.8 |
| 645 | 32.23 | |||||
| 5 | ATR | 4.90 | 725.0 | 543 | 48.33 | 0.8 |
| 645 | 23.45 | |||||
| 6 | Chloramphenicol (IS) | 6.22 | 321.0 | 152 | 10.23 | 0.8 |
| 257 | 10.23 |
Fig. 1UPLC-MS/MS analysis SRM chromatogram of five analytes: ATP (1), ADP (2), AMP (3), ATR (4), CATR (5), and IS (6) in different matrices.
Regression equation, correlation coefficients, linearity ranges, and LLOQs for five analytes
| Peak no. | Analytes | Calibration curves | Correlation coefficient, | Linear range (ng mL−1) | LLOQs (ng mL−1) |
|---|---|---|---|---|---|
| 1 | ATP |
| 0.9990 | 10.5–1080.5 | 10.5 |
| 2 | ADP |
| 0.9991 | 9.5–1180.5 | 9.5 |
| 3 | AMP |
| 0.9990 | 10.6–2070.0 | 10.6 |
| 4 | CATR |
| 0.9992 | 9.5–1450.5 | 9.5 |
| 5 | ATR |
| 0.9996 | 10.8–1480.0 | 10.8 |
Fig. 2ATP, ADP, and AMP levels in mice liver tissue 10, 20, and 30 days after oral administration. Values are means ± SD from six animals in each group. *p < 0.05, **p < 0.01 vs. control. #p < 0.05, ##p < 0.01 vs. RXF group.
Fig. 3ATR and CATR contents in liver tissue of ground RXF.